• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Preference for and impact of telehealth vs in-person asthma visits among Black and Latinx adults
Black and Latinx adults experience disproportionate asthma-related morbidity and limited specialty care access. The severe acute respiratory syndrome coronavirus 2 pandemic expanded telehealth use.
Source: Annals of Allergy, Asthma and Immunology - July 23, 2023 Category: Allergy & Immunology Authors: Israel C. Ugalde, Amanda Ratigan, Conner Merriman, Jing Cui, Brianna Ericson, Paula Busse, Jennifer K. Carroll, Thomas Casale, Juan Carlos Celed ón, Tamera Coyne-Beasley, Maureen Fagan, Anne L. Fuhlbrigge, Gabriela Gaona Villarreal, Paulina Arias Hernand Source Type: research

Specific antibody response of 14 common variable immunodeficiency patients to three BNT162b2 mRNA COVID-19 vaccinations
On December 20th, 2020 Israel conducted a vaccination campaign against the spread of coronavirus disease 2019 (COVID-19) with a two-dose regimen of Pfizer-BioNTech mRNA vaccine, BNT262b2. By June 1, 2021, 56% of the population was fully vaccinated.1 The emergence of the highly infectious delta variant and waning vaccine-elicited immunity contributed to a resurgence in both confirmed and severe illness. In June 2021 the number of PCR-confirmed cases increased substantially. Therefore, on July 12, 2021, Israeli authorities decided to administer a third booster dose.
Source: Annals of Allergy, Asthma and Immunology - April 5, 2022 Category: Allergy & Immunology Authors: Nizar Abo-Helo, Emad Muhammad, Sondus Ghaben-Amara, Shai Cohen Tags: Letter Source Type: research

Specific antibody response of 14 patients with common variable immunodeficiency to 3 BNT162b2 messenger RNA coronavirus disease 2019 vaccinations
On December 20, 2020, Israel conducted a vaccination campaign against the spread of coronavirus disease 2019 (COVID-19) with a 2-dose regimen of Pfizer-BioNTech messenger RNA vaccine, BNT262b2. By June 1, 2021, 56% of the population was fully vaccinated.1 The emergence of the highly infectious delta variant and waning of vaccine-elicited immunity contributed to a resurgence in both confirmed and severe illnesses. In June 2021, the number of polymerase chain reaction –confirmed cases increased substantially.
Source: Annals of Allergy, Asthma and Immunology - April 5, 2022 Category: Allergy & Immunology Authors: Nizar Abo-Helo, Emad Muhammad, Sondus Ghaben-Amara, Shai Cohen Tags: Letters Source Type: research

COVID-19 Vaccines Offer Strong Protection Against Reinfection COVID-19 Vaccines Offer Strong Protection Against Reinfection
Researchers in Israel analyzed electronic health records for more than 83,000 people who received at least one dose of the Pfizer vaccine after recovering from a previous coronavirus infection.WebMD Health News
Source: Medscape Allergy Headlines - February 22, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased with today’s Positiv...
Source: Johnson and Johnson - December 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
In mid-December 2020, Israel started a nationwide mass vaccination campaign against coronavirus disease 2019 (COVID-19). In the first few weeks, medical personnel, elderly citizens, and patients with chronic diseases were prioritized. As such, patients with primary and secondary immunodeficiencies were encouraged to receive the vaccine. Although the efficacy of RNA-based COVID-19 vaccines has been demonstrated in the general population, little is known about their efficacy and safety in patients with inborn errors of immunity (IEI).
Source: Journal of Allergy and Clinical Immunology - June 1, 2021 Category: Allergy & Immunology Authors: David Hagin, Tal Freund, Michal Navon, Tami Halperin, Dikla Adir, Rotem Marom, Inbar Levi, Shira Benor, Yifat Alcalay, Natalia T. Freund Source Type: research

We May Never Eliminate COVID-19. But We Can Learn to Live With It
When does a pandemic end? Is it when life regains a semblance of normality? Is it when the world reaches herd immunity, the benchmark at which enough people are immune to an infectious disease to stop its widespread circulation? Or is it when the disease is defeated, the last patient cured and the pathogen retired to the history books? The last scenario, in the case of COVID-19, is likely a ways off, if it ever arrives. The virus has infected more than 100 million people worldwide and killed more than 2 million. New viral variants even more contagious than those that started the pandemic are spreading across the world. And...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cover Story COVID-19 feature Magazine Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news

COVID19: Time to embrace MDI+ valved-holding chambers!
Because of the great transmissibility of the virus causing coronavirus disease 2019 (COVID-19), the use of small-volume nebulizers (SVNs) in these days may constitute a serious hazard.
Source: Journal of Allergy and Clinical Immunology - May 21, 2020 Category: Allergy & Immunology Authors: Israel Amirav, Michael T. Newhouse Tags: Correspondence Source Type: research

COVID-19: Time to embrace MDI+ valved-holding chambers!
Because of the great transmissibility of the virus causing coronavirus disease 2019 (COVID-19), the use of small-volume nebulizers (SVNs) in these days may constitute a serious hazard.
Source: Journal of Allergy and Clinical Immunology - May 21, 2020 Category: Allergy & Immunology Authors: Israel Amirav, Michael T. Newhouse Tags: Correspondence Source Type: research

Dr. Fauci: Drug Tested On Coronavirus Patients In Mass. Shows Promise
BOSTON (CBS) – Two Massachusetts hospitals, Massachusetts General Hospital and UMass Memorial, helped put the experimental drug Remdesivir to the test against COVID-19. They were part of an international independent study, and the results have those in the medical field optimistic. “It has proven that a drug can block this virus,” said Dr. Anthony Fauci of the National Institute of Allergy & Infectious Diseases as he announced promising news in the fight against COVID-19. Remdesivir. (Photo by ULRICH PERREY/POOL/AFP via Getty Images) The news comes from a federal study, one that UMass Memorial participated in...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 30, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Syndicated Local Coronavirus remdesivir Worcester news Source Type: news